Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline

Sam S. Chang, Stephen A. Boorjian, Roger Chou, Peter E. Clark, Siamak Daneshmand, Badrinath R. Konety, Raj Pruthi, Diane Z. Quale, Chad Ritch, John D. Seigne, Eila Curlee Skinner, Norm D. Smith, James M. McKiernan

Research output: Contribution to journalArticle

251 Citations (Scopus)

Abstract

Purpose Although associated with an overall favorable survival rate, the heterogeneity of non-muscle invasive bladder cancer (NMIBC) affects patients’ rates of recurrence and progression. Risk stratification should influence evaluation, treatment and surveillance. This guideline attempts to provide a clinical framework for the management of NMIBC. Materials and Methods A systematic review utilized research from the Agency for Healthcare Research and Quality (AHRQ) and additional supplementation by the authors and consultant methodologists. Evidence-based statements were based on body of evidence strength Grade A, B, or C and were designated as Strong, Moderate, and Conditional Recommendations with additional statements presented in the form of Clinical Principles or Expert Opinions.1 Results A risk-stratified approach categorizes patients into broad groups of low-, intermediate-, and high-risk. Importantly, the evaluation and treatment algorithm takes into account tumor characteristics and uniquely considers a patient's response to therapy. The 38 statements vary in level of evidence, but none include Grade A evidence, and many were Grade C. Conclusion The intensity and scope of care for NMIBC should focus on patient, disease, and treatment response characteristics. This guideline attempts to improve a clinician's ability to evaluate and treat each patient, but higher quality evidence in future trials will be essential to improve level of care for these patients.

Original languageEnglish (US)
Pages (from-to)1021-1029
Number of pages9
JournalJournal of Urology
Volume196
Issue number4
DOIs
StatePublished - Oct 1 2016
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Guidelines
Therapeutics
Health Services Research
Consultants
Survival Rate
Recurrence
Research
Neoplasms

Keywords

  • cystectomy
  • drug therapy
  • immunotherapy
  • urinary bladder neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Chang, S. S., Boorjian, S. A., Chou, R., Clark, P. E., Daneshmand, S., Konety, B. R., ... McKiernan, J. M. (2016). Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. Journal of Urology, 196(4), 1021-1029. https://doi.org/10.1016/j.juro.2016.06.049

Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer : AUA/SUO Guideline. / Chang, Sam S.; Boorjian, Stephen A.; Chou, Roger; Clark, Peter E.; Daneshmand, Siamak; Konety, Badrinath R.; Pruthi, Raj; Quale, Diane Z.; Ritch, Chad; Seigne, John D.; Skinner, Eila Curlee; Smith, Norm D.; McKiernan, James M.

In: Journal of Urology, Vol. 196, No. 4, 01.10.2016, p. 1021-1029.

Research output: Contribution to journalArticle

Chang, SS, Boorjian, SA, Chou, R, Clark, PE, Daneshmand, S, Konety, BR, Pruthi, R, Quale, DZ, Ritch, C, Seigne, JD, Skinner, EC, Smith, ND & McKiernan, JM 2016, 'Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline', Journal of Urology, vol. 196, no. 4, pp. 1021-1029. https://doi.org/10.1016/j.juro.2016.06.049
Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. Journal of Urology. 2016 Oct 1;196(4):1021-1029. https://doi.org/10.1016/j.juro.2016.06.049
Chang, Sam S. ; Boorjian, Stephen A. ; Chou, Roger ; Clark, Peter E. ; Daneshmand, Siamak ; Konety, Badrinath R. ; Pruthi, Raj ; Quale, Diane Z. ; Ritch, Chad ; Seigne, John D. ; Skinner, Eila Curlee ; Smith, Norm D. ; McKiernan, James M. / Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer : AUA/SUO Guideline. In: Journal of Urology. 2016 ; Vol. 196, No. 4. pp. 1021-1029.
@article{affcef57ae914af39541acb73b1acd69,
title = "Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline",
abstract = "Purpose Although associated with an overall favorable survival rate, the heterogeneity of non-muscle invasive bladder cancer (NMIBC) affects patients’ rates of recurrence and progression. Risk stratification should influence evaluation, treatment and surveillance. This guideline attempts to provide a clinical framework for the management of NMIBC. Materials and Methods A systematic review utilized research from the Agency for Healthcare Research and Quality (AHRQ) and additional supplementation by the authors and consultant methodologists. Evidence-based statements were based on body of evidence strength Grade A, B, or C and were designated as Strong, Moderate, and Conditional Recommendations with additional statements presented in the form of Clinical Principles or Expert Opinions.1 Results A risk-stratified approach categorizes patients into broad groups of low-, intermediate-, and high-risk. Importantly, the evaluation and treatment algorithm takes into account tumor characteristics and uniquely considers a patient's response to therapy. The 38 statements vary in level of evidence, but none include Grade A evidence, and many were Grade C. Conclusion The intensity and scope of care for NMIBC should focus on patient, disease, and treatment response characteristics. This guideline attempts to improve a clinician's ability to evaluate and treat each patient, but higher quality evidence in future trials will be essential to improve level of care for these patients.",
keywords = "cystectomy, drug therapy, immunotherapy, urinary bladder neoplasms",
author = "Chang, {Sam S.} and Boorjian, {Stephen A.} and Roger Chou and Clark, {Peter E.} and Siamak Daneshmand and Konety, {Badrinath R.} and Raj Pruthi and Quale, {Diane Z.} and Chad Ritch and Seigne, {John D.} and Skinner, {Eila Curlee} and Smith, {Norm D.} and McKiernan, {James M.}",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.juro.2016.06.049",
language = "English (US)",
volume = "196",
pages = "1021--1029",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer

T2 - AUA/SUO Guideline

AU - Chang, Sam S.

AU - Boorjian, Stephen A.

AU - Chou, Roger

AU - Clark, Peter E.

AU - Daneshmand, Siamak

AU - Konety, Badrinath R.

AU - Pruthi, Raj

AU - Quale, Diane Z.

AU - Ritch, Chad

AU - Seigne, John D.

AU - Skinner, Eila Curlee

AU - Smith, Norm D.

AU - McKiernan, James M.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Purpose Although associated with an overall favorable survival rate, the heterogeneity of non-muscle invasive bladder cancer (NMIBC) affects patients’ rates of recurrence and progression. Risk stratification should influence evaluation, treatment and surveillance. This guideline attempts to provide a clinical framework for the management of NMIBC. Materials and Methods A systematic review utilized research from the Agency for Healthcare Research and Quality (AHRQ) and additional supplementation by the authors and consultant methodologists. Evidence-based statements were based on body of evidence strength Grade A, B, or C and were designated as Strong, Moderate, and Conditional Recommendations with additional statements presented in the form of Clinical Principles or Expert Opinions.1 Results A risk-stratified approach categorizes patients into broad groups of low-, intermediate-, and high-risk. Importantly, the evaluation and treatment algorithm takes into account tumor characteristics and uniquely considers a patient's response to therapy. The 38 statements vary in level of evidence, but none include Grade A evidence, and many were Grade C. Conclusion The intensity and scope of care for NMIBC should focus on patient, disease, and treatment response characteristics. This guideline attempts to improve a clinician's ability to evaluate and treat each patient, but higher quality evidence in future trials will be essential to improve level of care for these patients.

AB - Purpose Although associated with an overall favorable survival rate, the heterogeneity of non-muscle invasive bladder cancer (NMIBC) affects patients’ rates of recurrence and progression. Risk stratification should influence evaluation, treatment and surveillance. This guideline attempts to provide a clinical framework for the management of NMIBC. Materials and Methods A systematic review utilized research from the Agency for Healthcare Research and Quality (AHRQ) and additional supplementation by the authors and consultant methodologists. Evidence-based statements were based on body of evidence strength Grade A, B, or C and were designated as Strong, Moderate, and Conditional Recommendations with additional statements presented in the form of Clinical Principles or Expert Opinions.1 Results A risk-stratified approach categorizes patients into broad groups of low-, intermediate-, and high-risk. Importantly, the evaluation and treatment algorithm takes into account tumor characteristics and uniquely considers a patient's response to therapy. The 38 statements vary in level of evidence, but none include Grade A evidence, and many were Grade C. Conclusion The intensity and scope of care for NMIBC should focus on patient, disease, and treatment response characteristics. This guideline attempts to improve a clinician's ability to evaluate and treat each patient, but higher quality evidence in future trials will be essential to improve level of care for these patients.

KW - cystectomy

KW - drug therapy

KW - immunotherapy

KW - urinary bladder neoplasms

UR - http://www.scopus.com/inward/record.url?scp=84995939797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995939797&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2016.06.049

DO - 10.1016/j.juro.2016.06.049

M3 - Article

C2 - 27317986

AN - SCOPUS:84995939797

VL - 196

SP - 1021

EP - 1029

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 4

ER -